The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra): Interim analysis of the RALU study.
 
Kambiz Rahbar
Honoraria - Advanced Accelerator Applications/Novartis; Bayer
Consulting or Advisory Role - ABX Advanced biochemical compounds; ABX-CRO; Advanced Accelerator Applications; Bayer
 
Markus Essler
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Ipsen
Travel, Accommodations, Expenses - Ipsen
 
Matthias Eiber
Stock and Other Ownership Interests - Novartis; Telix Pharmaceuticals; Telix Pharmaceuticals
Consulting or Advisory Role - ABX Advanced biochemical compounds; Blue Earth Diagnostics; Janssen Oncology; Novartis (Inst); Telix Pharmaceuticals
Research Funding - ABX Advanced biochemical compounds; Bayer (Inst); Blue Earth Diagnostics (Inst); Siemens
Patents, Royalties, Other Intellectual Property - patent application for rhPSMA
Travel, Accommodations, Expenses - Bayer Schering Pharma
 
Christian la Fougère
Consulting or Advisory Role - EUSA Pharma; Ipsen; Novartis; Oncodesign; Sirtex Medical
Research Funding - Oncovision (Inst)
 
Vikas Prasad
Honoraria - Advanced Accelerator Applications/Novartis
Consulting or Advisory Role - Bayer
Research Funding - Ipsen
 
Wolfgang P. Fendler
Honoraria - Parexel
Consulting or Advisory Role - Calyx; Janssen
Speakers' Bureau - Bayer; Janssen
Research Funding - SOFIE
 
Philipp Rassek
No Relationships to Disclose
 
Ergela Hasa
No Relationships to Disclose
 
Helmut Dittmann
No Relationships to Disclose
 
Ralph A. Bundschuh
Honoraria - Eisai
Consulting or Advisory Role - Bayer
 
Kim M. Pabst
No Relationships to Disclose
 
Milena Kurtinecz
Employment - Bayer
 
Per Sandstrom
Employment - Bayer
Stock and Other Ownership Interests - InVitae; Oasmia Pharmaceutical AB
 
Frank Verholen
Employment - Bayer
Travel, Accommodations, Expenses - Bayer
 
A. Oliver Sartor
Stock and Other Ownership Interests - Abbvie; Cardinal Health; Clarity Pharmaceuticals; Clovis Oncology; GlaxoSmithKline; Lilly; Noria Therapeutics; PSMA Therapeutics; United Health Group
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Clarity Pharmaceuticals; Clovis Oncology; Constellation Pharmaceuticals; Dendreon; EMD Serono; Fusion Pharmaceuticals; Isotopen Technologien; Janssen; Myovant Sciences; Myriad Genetics; Noria Therapeutics; Novartis; Noxopharm; Pfizer; Point Biopharma; Progenics; Sanofi; Telix Pharmaceuticals; TeneoBio; Theragnostics
Research Funding - Advanced Accelerator Applications (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Endocyte (Inst); InVitae (Inst); Janssen; Lantheus Medical Imaging (Inst); Merck (Inst); Progenics; Sanofi (Inst); SOTIO
Patents, Royalties, Other Intellectual Property - Koochekpour, Sartor AO, inventors. Saposin C and receptors as targets for treatment of benign and malignant disorders. US patent awarded January 23, 2007 (patent no. 7,166,691).
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Progenics; Sanofi